Stockholm, December 6, 2024 - Intervacc AB (publ) announces that Strangvac, a vaccine against equine strangles, is now back in stock for delivery in all European markets where the vaccine has been launched.

The company applied for Special Batch Release (SBR), to allow for the recently manufactured batches to be available for sale. Today, the company can announce that after receiving approval for SBR in all local markets, Strangvac is available for immediate delivery in all markets where the product has been launched.

The procedure and processes, including the Special Batch Release, have been different in different countries, and the time required to make Strangvac available again in the various markets has therefore varied.

"We are very pleased that the Medical Products Agencies around Europe have acted diligently, which has made it possible for Strangvac to be available again for immediate delivery." commented CEO Jonas Sohlman.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on December 6, 2024, 12.45 p.m. CET.

About Strangvac

Strangvac, a vaccine against equine strangles, is approved for sale and marketing in the EU, as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, and Italy.

About Intervacc

Intervacc AB (publ) is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is listed on NASDAQ First North Growth Market.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10